US FDA Reviewing Data To Determine Need For Biosimilar Suffixes

 
• By Derrick Gingery
  
FDA staff will review biosimilar adverse event databases to determine whether the nonproprietary name suffix still is necessary. (Shutterstock)

More from Biosimilars

More from United States